Agreement Of Pathological Diagnosis In Fibrosing Interstitial Pneumonia
Junya Fukuoka(University of Nagasaki), Fumio Yamasaki, Hideki Origasa(University of Toyama), Shigeki Shimizu(Kindai University), John C. English(University of British Columbia Hospital), Mary Beth Beasley(Icahn School of Medicine at Mount Sinai), Élisabeth Brambilla(Centre National de la Recherche Scientifique), Yasuhiro Kondoh, Ichiro Yamadori(National Hospital Organization), Masanori Kitaichi(Minami Wakayama Medical Center), Ryoko Egashira, Hiroyuki Takahashi(Yokohama City University), William D. Travis(Memorial Sloan Kettering Cancer Center), Françoise Galateau-Sallé(Collège de France), Shinichi Hayashi(Saitama Cancer Center), Kirk D. Jones, Thomas V. Colby(Mayo Clinic in Arizona), Bruno Murer, Tomayoshi Hayashi, Henry D. Tazelaar(Mayo Clinic in Arizona), Marcio M. Gomes, Yutaka Tsutsumi, Akira Hebisawa, Yoshinori Kawabata(Saitama Prefecture), Tamiko Takemura, Kazuhiro Nomoto, Hiroyuki Taniguchi(Tosei General Hospital), Timothy Allen, Teruaki Oka(Saitama Medical University), Neil A. Abrahams, Naoko Kumagai(Tohoku University), Shin Ishizawa, Keith M. Kerr(University of Aberdeen), Kensuke Kataoka, Yuh Fukuda, Tomonori Tanaka
Cited by 0
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k